CO7020915A2 - Iap inhibitors - Google Patents

Iap inhibitors

Info

Publication number
CO7020915A2
CO7020915A2 CO14161919A CO14161919A CO7020915A2 CO 7020915 A2 CO7020915 A2 CO 7020915A2 CO 14161919 A CO14161919 A CO 14161919A CO 14161919 A CO14161919 A CO 14161919A CO 7020915 A2 CO7020915 A2 CO 7020915A2
Authority
CO
Colombia
Prior art keywords
iap inhibitors
iap
inhibitors
see annex
annex
Prior art date
Application number
CO14161919A
Other languages
Spanish (es)
Inventor
John A Flygare
Frederick Cohen
Lewis J Gazzard
Vickie Hsiao-Wei Tsui
Original Assignee
Curis Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Genentech Inc filed Critical Curis Inc
Publication of CO7020915A2 publication Critical patent/CO7020915A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

VER ANEXOSEE ANNEX

CO14161919A 2012-01-03 2014-07-25 Iap inhibitors CO7020915A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03

Publications (1)

Publication Number Publication Date
CO7020915A2 true CO7020915A2 (en) 2014-08-11

Family

ID=48695302

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14161919A CO7020915A2 (en) 2012-01-03 2014-07-25 Iap inhibitors

Country Status (41)

Country Link
US (6) US8716236B2 (en)
EP (2) EP3133073B1 (en)
JP (2) JP5747137B2 (en)
KR (3) KR101917992B1 (en)
CN (2) CN104159897A (en)
AR (2) AR089623A1 (en)
AU (1) AU2013202780B2 (en)
BR (1) BR112014016637B1 (en)
CA (1) CA2861637C (en)
CL (1) CL2014001770A1 (en)
CO (1) CO7020915A2 (en)
CR (1) CR20140367A (en)
CY (2) CY1118371T1 (en)
DK (2) DK2800749T3 (en)
EC (1) ECSP14011792A (en)
ES (2) ES2672809T3 (en)
HK (1) HK1203949A1 (en)
HR (2) HRP20161381T1 (en)
HU (2) HUE031305T2 (en)
IL (2) IL233386A (en)
LT (2) LT3133073T (en)
MA (1) MA35895B1 (en)
ME (2) ME03084B (en)
MX (1) MX336294B (en)
MY (1) MY178390A (en)
NO (1) NO2755614T3 (en)
NZ (1) NZ627480A (en)
PE (1) PE20142182A1 (en)
PH (2) PH12014501534A1 (en)
PL (2) PL3133073T3 (en)
PT (2) PT3133073T (en)
RS (2) RS55327B1 (en)
RU (2) RU2593259C2 (en)
SG (1) SG11201403784QA (en)
SI (2) SI2800749T1 (en)
SM (1) SMT201600357B (en)
TR (1) TR201808088T4 (en)
TW (1) TWI503318B (en)
UA (1) UA114417C2 (en)
WO (1) WO2013103703A1 (en)
ZA (1) ZA201405535B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (en) * 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (en) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 IAP inhibitors and their use in medicine
AU2018364218B2 (en) * 2017-11-13 2023-03-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SMAC mimetics used as IAP inhibitors and use thereof
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. Heterocyclic compound
JPWO2021020585A1 (en) 2019-07-31 2021-02-04
CA3166980A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2022463015A1 (en) 2021-10-22 2024-05-09 Tract Pharmaceuticals, Inc. Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1998046576A2 (en) 1997-04-15 1998-10-22 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
DK1778718T3 (en) * 2004-07-02 2014-11-10 Genentech Inc IAP INHIBITORS
NZ589670A (en) * 2004-12-20 2013-01-25 Genentech Inc Pyrrolidine inhibitors of iap
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
NO2755614T3 (en) 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
HUE031305T2 (en) 2017-07-28
LT3133073T (en) 2018-06-25
EP3133073A2 (en) 2017-02-22
KR20140107670A (en) 2014-09-04
HRP20180976T1 (en) 2018-08-10
BR112014016637B1 (en) 2022-06-14
PH12014501534B1 (en) 2014-10-08
HK1203949A1 (en) 2015-11-06
JP5747137B2 (en) 2015-07-08
US9238675B2 (en) 2016-01-19
AU2013202780B2 (en) 2015-04-16
KR101855566B1 (en) 2018-05-04
ME03084B (en) 2019-01-20
US20190224269A1 (en) 2019-07-25
NO2755614T3 (en) 2018-03-31
KR101553792B1 (en) 2015-09-16
ECSP14011792A (en) 2015-12-31
AR089623A1 (en) 2014-09-03
MX2014007895A (en) 2015-03-19
US20130172264A1 (en) 2013-07-04
DK2800749T3 (en) 2016-11-07
RU2728789C2 (en) 2020-07-31
PL3133073T3 (en) 2018-09-28
PT3133073T (en) 2018-06-18
MX336294B (en) 2016-01-14
EP3133073A3 (en) 2017-03-22
US20140235551A1 (en) 2014-08-21
KR101917992B1 (en) 2018-11-13
MA35895B1 (en) 2014-12-01
US20220211797A1 (en) 2022-07-07
ME02526B (en) 2017-02-20
KR20150065960A (en) 2015-06-15
PE20142182A1 (en) 2015-01-16
CR20140367A (en) 2015-02-18
BR112014016637A8 (en) 2017-07-04
JP2015199738A (en) 2015-11-12
CN104159897A (en) 2014-11-19
MY178390A (en) 2020-10-12
US20170136084A1 (en) 2017-05-18
UA114417C2 (en) 2017-06-12
SI2800749T1 (en) 2016-11-30
BR112014016637A2 (en) 2017-06-13
AR123542A2 (en) 2022-12-14
US20160102119A1 (en) 2016-04-14
PH12015501038A1 (en) 2015-09-21
PH12014501534A1 (en) 2014-10-08
HRP20161381T1 (en) 2016-12-02
CY1118371T1 (en) 2017-06-28
CY1120355T1 (en) 2019-07-10
EP2800749B1 (en) 2016-09-21
CL2014001770A1 (en) 2015-04-17
TR201808088T4 (en) 2018-06-21
EP2800749A1 (en) 2014-11-12
EP3133073B1 (en) 2018-05-02
US11096982B2 (en) 2021-08-24
IL233386A (en) 2016-08-31
PL2800749T3 (en) 2017-01-31
SI3133073T1 (en) 2018-06-29
CN107915728A (en) 2018-04-17
SG11201403784QA (en) 2014-08-28
EP2800749A4 (en) 2015-08-05
HUE037760T2 (en) 2018-09-28
RS55327B1 (en) 2017-03-31
US9586991B2 (en) 2017-03-07
RU2014130171A (en) 2016-02-27
PT2800749T (en) 2016-10-24
RU2016124658A (en) 2018-12-04
ES2672809T3 (en) 2018-06-18
IL242314A (en) 2016-08-31
KR20180051646A (en) 2018-05-16
ZA201405535B (en) 2017-08-30
WO2013103703A1 (en) 2013-07-11
PH12015501038B1 (en) 2015-09-21
JP2015504072A (en) 2015-02-05
DK3133073T3 (en) 2018-06-18
CN107915728B (en) 2021-04-30
TW201333001A (en) 2013-08-16
ES2594856T3 (en) 2016-12-23
RU2593259C2 (en) 2016-08-10
IL233386A0 (en) 2014-08-31
TWI503318B (en) 2015-10-11
LT2800749T (en) 2016-10-25
US11963994B2 (en) 2024-04-23
RU2016124658A3 (en) 2019-09-09
AU2013202780A1 (en) 2013-07-18
SMT201600357B (en) 2016-11-10
CA2861637C (en) 2017-07-18
RS57438B1 (en) 2018-09-28
NZ627480A (en) 2016-04-29
US8716236B2 (en) 2014-05-06
CA2861637A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
HRP20190373T1 (en) Dna-pk inhibitors
CO7111289A2 (en) Metalloenzyme inhibitor compounds
DK3459942T3 (en) DNA-PK inhibitors
RS57306B1 (en) Dna-pk inhibitors
SMT201600114B (en) BETA-SECRETASI INHIBITORS
CO7020915A2 (en) Iap inhibitors
BR112014026634A2 (en) driver
HK1222848A1 (en) Pyrrolotriazines as alk inhibitors alk
BR112014027219A2 (en) method
FR2997080B1 (en) INHIBITORS OF NEPRILYSINE
ECSP15017165A (en) HISTONE DEMETILASE INHIBITORS
TN2011000287A1 (en) حذاء مولد للطاقة